Vaxcyte, Inc.
PCVX
Rang în acțiuni
#2073
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Preț acțiune
$63.82
Capitalizare de piață
$10.04B
Schimbare (1 zi)
-3.64%
Schimbare (1 an)
50.70%
Țară
US
Tranzacționează Vaxcyte, Inc. (PCVX)
Categorie
Healthcare
Istoric al prețului acțiunii pentru Vaxcyte, Inc. (PCVX)
Cel mai mare preț de închidere: $65.60 pe 2026-10-01
Cel mai mic preț de închidere: $32.16 pe 2020-06-01
Cel mai mic preț de închidere: $32.16 pe 2020-06-01
Istoric al prețului acțiunii pentru Vaxcyte, Inc. din 2020 până în 2026
Evoluția anuală a prețului acțiunii
| An | Performanță |
|---|---|
| 2026 (TTM) | 18.84% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Prețul acțiunii pentru companii similare sau concurente
| Companie | Preț acțiune | Variație 1an% | Țara |
|---|---|---|---|
| $518.20 | 21.57% |
US
|
|
| $243.77 | 786.76% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $879.20 | 5.32% |
NL
|
|
| $752.87 | 7.40% |
CH
|
